Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death globally, and the leading cause of mortality in cirrhotic patients, with hepatitis C virus (HCV) being the major risk factor in the Western world and Japan. [1] Orthotopic liver transplantation (OLT) is the definitive treatment for HCC and cirrhotic liver, but this approach cannot be offered to all patients due to limited graft availability and rigorous selection criteria. [2] Alternative curative treatment options for patients with compensated cirrhosis are surgical resection and loco-regional ablation of early (i.e., stage 0/A) Barcelona Clinic Liver Cancer (BCLC).

Source: Journal of Hepatology - April 4, 2019 Category: Gastroenterology Authors: Giuseppe Cabibbo, Ciro Celsa, Vincenza Calvaruso, Salvatore Petta, Irene Cacciola, Maria Rita Cannav ò, Salvatore Madonia, Margherita Rossi, Bianca Magro, Francesca Rini, Marco Distefano, Licia Larocca, Tullio Prestileo, Giuseppe Malizia, Gaetano Bertino Source Type: research